News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Algorithme Pharma Release: the 505(b)(2) Approval Pathway



5/30/2013 12:12:57 PM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

May 2013 -- The 505(b)(2) pathway provides an accelerated timeline to approval for a wide range of new drug applications involving already approved drug molecules.

The key to a viable 505(b)(2) New Drug Application (NDA) development strategy is identifying existing submission gaps early, and then planning for studies that will effectively bridge those gaps. Algorithme Pharma offers scientific guidance in developing a clinical study design to address critical endpoints such as safety, pharmacokinetics and pharmacodynamics in accordance with 505(b)(2) regulatory criteria.

Algorithme Pharma has recently conducted more than 50 clinical trials for multiple 505(b)(2) targeted filings, where several have received Food and Drug Administration (FDA) approvals. Our most recent audit, in March 2013, successfully met all requirements in the FDA inspection of our clinical, bioanalytical and phamacokinetics units. With high quality 505(b)(2) trial conduct and individualized clinical program guidance, Algorithme Pharma continues to support sponsors in successfully navigating this development pathway.

For more information regarding our 505(b)(2) services, please contact us at contact@algopharm.com.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES